BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281:13548-13558. [PMID: 16533812 DOI: 10.1074/jbc.m510023200] [Cited by in Crossref: 368] [Cited by in F6Publishing: 199] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9. [PMID: 19029799 DOI: 10.4161/epi.3.6.7273] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 6.1] [Reference Citation Analysis]
2 Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 2011;6:e18087. [PMID: 21464950 DOI: 10.1371/journal.pone.0018087] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
3 Aseem O, Barth JL, Klatt SC, Smith BT, Argraves WS. Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics 2013;14:405. [PMID: 23773363 DOI: 10.1186/1471-2164-14-405] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
4 Bhatia H, Hallock JL, Dutta A, Karkashon S, Sterner LS, Miyazaki T, Dean A, Little JA. Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells. Blood 2009;113:6440-8. [PMID: 19380871 DOI: 10.1182/blood-2008-09-171728] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hofmanová J, Slavík J, Ovesná P, Tylichová Z, Vondráček J, Straková N, Vaculová AH, Ciganek M, Kozubík A, Knopfová L, Šmarda J, Machala M. Dietary fatty acids specifically modulate phospholipid pattern in colon cells with distinct differentiation capacities. Eur J Nutr 2017;56:1493-508. [PMID: 26983609 DOI: 10.1007/s00394-016-1196-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Zeng LS, Yang XZ, Wen YF, Mail SJ, Wang MH, Zhang MY, Zheng XF, Wang HY. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY). 2016;8:1236-1249. [PMID: 27295551 DOI: 10.18632/aging.100980] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
7 Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC, Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 2011;17:589-97. [PMID: 21115653 DOI: 10.1158/1078-0432.CCR-10-0738] [Cited by in Crossref: 68] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
8 Knackstedt RW, Moseley VR, Wargovich MJ. Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancer. Anticancer Agents Med Chem 2012;12:1203-10. [PMID: 22931412 DOI: 10.2174/187152012803833053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kotian S, Liyanarachchi S, Zelent A, Parvin JD. Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 2011;286:7722-6. [PMID: 21247901 DOI: 10.1074/jbc.C110.194233] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
10 Griess B, Tom E, Domann F, Teoh-Fitzgerald M. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med 2017;112:464-79. [PMID: 28842347 DOI: 10.1016/j.freeradbiomed.2017.08.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
11 Huang EC, Zhao Y, Chen G, Baek SJ, McEntee MF, Minkin S, Biggerstaff JP, Whelan J. Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. BMC Complement Altern Med 2014;14:68. [PMID: 24555771 DOI: 10.1186/1472-6882-14-68] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
12 Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898-3941. [PMID: 25738536 DOI: 10.3390/molecules20033898] [Cited by in Crossref: 415] [Cited by in F6Publishing: 378] [Article Influence: 59.3] [Reference Citation Analysis]
13 Abdelkarim H, Brunsteiner M, Neelarapu R, Bai H, Madriaga A, van Breemen RB, Blond SY, Gaponenko V, Petukhov PA. Photoreactive "nanorulers" detect a novel conformation of full length HDAC3-SMRT complex in solution. ACS Chem Biol 2013;8:2538-49. [PMID: 24010878 DOI: 10.1021/cb400601g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
14 Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 2014;62:11-33. [PMID: 24051359 DOI: 10.1369/0022155413506582] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
15 Manzotti G, Ciarrocchi A, Sancisi V. Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers (Basel) 2019;11:E304. [PMID: 30841549 DOI: 10.3390/cancers11030304] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
16 Inchiosa MA Jr. Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases. PLoS One 2018;13:e0198514. [PMID: 29897996 DOI: 10.1371/journal.pone.0198514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Xu X, Vatsyayan J, Gao C, Bakkenist CJ, Hu J. HDAC2 promotes eIF4E sumoylation and activates mRNA translation gene specifically. J Biol Chem 2010;285:18139-43. [PMID: 20421305 DOI: 10.1074/jbc.C110.131599] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
18 Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q, Jiang SW. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011;7:1415-28. [PMID: 22112317 DOI: 10.2217/fon.11.124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
19 D'Mello SR. Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect 2009;22:513-24. [PMID: 20072728 DOI: 10.1358/dnp.2009.9.1428871] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
20 Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci 2021;28:27. [PMID: 33840388 DOI: 10.1186/s12929-021-00721-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, Lichenstein H, Jensen PB, Sehested M. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer 2008;7:70. [PMID: 18789133 DOI: 10.1186/1476-4598-7-70] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
22 Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer 2015;6:184-213. [PMID: 26124919 DOI: 10.18632/genesandcancer.65] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
23 Hoshino I, Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surg Today 2010;40:809-15. [PMID: 20740342 DOI: 10.1007/s00595-010-4300-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
24 Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B, Ouaissi A. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011;2011:315939. [PMID: 20981265 DOI: 10.1155/2011/315939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
25 Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 2013;4:e519. [PMID: 23449455 DOI: 10.1038/cddis.2013.9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 13.4] [Reference Citation Analysis]
26 Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 2015;126:2392-403. [PMID: 26447190 DOI: 10.1182/blood-2015-03-632984] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
27 Negmeldin AT, Pflum MKH. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Bioorg Med Chem Lett 2017;27:3254-8. [PMID: 28648461 DOI: 10.1016/j.bmcl.2017.06.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, Löhr CV, Williams DE, Ho E. Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. Clin Epigenetics. 2015;7:102. [PMID: 26388957 DOI: 10.1186/s13148-015-0132-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
29 Ishola AA, Adewole KE. Phytosterols and triterpenes from Morinda lucida Benth. exhibit binding tendency against class I HDAC and HDAC7 isoforms. Mol Biol Rep 2019;46:2307-25. [PMID: 30771146 DOI: 10.1007/s11033-019-04689-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
30 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(20): 1951-1955 [DOI: 10.11569/wcjd.v14.i20.1951] [Reference Citation Analysis]
31 Wang X, Wang Y, Snitow ME, Stewart KM, Li S, Lu M, Morrisey EE. Expression of histone deacetylase 3 instructs alveolar type I cell differentiation by regulating a Wnt signaling niche in the lung. Dev Biol 2016;414:161-9. [PMID: 27141870 DOI: 10.1016/j.ydbio.2016.04.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
32 Zhang Q, Song Y, Chen W, Wang X, Miao Z, Cao L, Li F, Wang G. By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget 2015;6:16461-70. [PMID: 26098774 DOI: 10.18632/oncotarget.3889] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
33 Gadwal A, Modi A, Khokhar M, Vishnoi JR, Choudhary R, Elhence P, Banerjee M, Purohit P. Critical appraisal of epigenetic regulation of galectins in cancer. Int J Clin Oncol 2021. [PMID: 34652614 DOI: 10.1007/s10147-021-02048-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Müller BM, Bahra M, Neuhaus P, Dietel M. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer. 2009;9:395. [PMID: 19912635 DOI: 10.1186/1471-2407-9-395] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
35 Rikiishi H. Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) 2010;2:2026-43. [PMID: 24281216 DOI: 10.3390/cancers2042026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
36 Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2013;32:21-30. [PMID: 22059907 DOI: 10.5732/cjc.011.10245] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
37 Elmallah MIY, Micheau O. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. Cancers (Basel) 2019;11:E850. [PMID: 31248188 DOI: 10.3390/cancers11060850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
38 Wang D. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 2009;9:241-56. [PMID: 19355989 DOI: 10.2174/156802609788085287] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
39 Alleyne D, Witonsky DB, Mapes B, Nakagome S, Sommars M, Hong E, Muckala KA, Di Rienzo A, Kupfer SS. Colonic transcriptional response to 1α,25(OH)2 vitamin D3 in African- and European-Americans. J Steroid Biochem Mol Biol 2017;168:49-59. [PMID: 28163244 DOI: 10.1016/j.jsbmb.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
40 Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T, Trouche D. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol 2007;27:554-67. [PMID: 17101790 DOI: 10.1128/MCB.00869-06] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
41 Zhu BY, Shang BY, Du Y, Li Y, Li L, Xu XD, Zhen YS. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. Oncotarget. 2017;8:14748-14758. [PMID: 28107195 DOI: 10.18632/oncotarget.14714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
42 Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One. 2013;8:e69992. [PMID: 23922886 DOI: 10.1371/journal.pone.0069992] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
43 Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008;19:4062-75. [PMID: 18632985 DOI: 10.1091/mbc.e08-02-0139] [Cited by in Crossref: 145] [Cited by in F6Publishing: 103] [Article Influence: 10.4] [Reference Citation Analysis]
44 Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 2009;15:3189-95. [PMID: 19383814 DOI: 10.1158/1078-0432.CCR-08-2999] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
45 Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev. 2008;22:2639-2644. [PMID: 18832068 DOI: 10.1101/gad.484108] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
46 Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014;71:3885-901. [PMID: 24898083 DOI: 10.1007/s00018-014-1656-6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
47 Shan X, Fu YS, Aziz F, Wang XQ, Yan Q, Liu JW. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS One 2014;9:e115401. [PMID: 25521755 DOI: 10.1371/journal.pone.0115401] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
48 Hwang J, Lee JA, Pallas DC. Leucine Carboxyl Methyltransferase 1 (LCMT-1) Methylates Protein Phosphatase 4 (PP4) and Protein Phosphatase 6 (PP6) and Differentially Regulates the Stable Formation of Different PP4 Holoenzymes. J Biol Chem 2016;291:21008-19. [PMID: 27507813 DOI: 10.1074/jbc.M116.739920] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
49 Alcarraz-Vizán G, Boren J, Lee WN, Cascante M. Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics 2010;6:229-37. [PMID: 20445757 DOI: 10.1007/s11306-009-0192-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
50 Wang Z, Cao H, Sun Y, Li X, Chen F, Carles A, Li Y, Ding M, Zhang C, Deng X, Soppe WJ, Liu YX. Arabidopsis paired amphipathic helix proteins SNL1 and SNL2 redundantly regulate primary seed dormancy via abscisic acid-ethylene antagonism mediated by histone deacetylation. Plant Cell 2013;25:149-66. [PMID: 23371947 DOI: 10.1105/tpc.112.108191] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 9.3] [Reference Citation Analysis]
51 Sholler GS, Currier EA, Dutta A, Slavik MA, Illenye SA, Mendonca MC, Dragon J, Roberts SS, Bond JP. PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J Cancer Ther Res 2013;2:21. [PMID: 25520806 DOI: 10.7243/2049-7962-2-21] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
52 Min SK, Koh YH, Park Y, Kim HJ, Seo J, Park HR, Cho SJ, Kim IS. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol 2012;46:142-50. [PMID: 23109994 DOI: 10.4132/KoreanJPathol.2012.46.2.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
53 Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol 2014;4:111. [PMID: 24904826 DOI: 10.3389/fonc.2014.00111] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
54 Wang LT, Liou JP, Li YH, Liu YM, Pan SL, Teng CM. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin. Oncotarget 2014;5:5651-62. [PMID: 25015091 DOI: 10.18632/oncotarget.2155] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
55 Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C, Lazar MA. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev. 2006;20:2566-2579. [PMID: 16980585 DOI: 10.1101/gad.1455006] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 7.7] [Reference Citation Analysis]
56 Kwon Y, Kim Y, Jung HS, Jeoung D. Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance. Int J Mol Sci 2018;20:E51. [PMID: 30583572 DOI: 10.3390/ijms20010051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
57 Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-77. [PMID: 18671804 DOI: 10.1111/j.0309-0167.2008.03109.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 45] [Article Influence: 0.2] [Reference Citation Analysis]
58 Algamas-Dimantov A, Yehuda-Shnaidman E, Peri I, Schwartz B. Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy. Cell Oncol (Dordr) 2013;36:155-67. [PMID: 23307400 DOI: 10.1007/s13402-012-0123-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
59 Cheng-Sánchez I, García-Ruiz C, Guerrero-Vásquez GA, Sarabia F. An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues. J Org Chem 2017;82:4744-57. [PMID: 28397496 DOI: 10.1021/acs.joc.7b00424] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
60 Roostaee A, Benoit YD, Boudjadi S, Beaulieu JF. Epigenetics in Intestinal Epithelial Cell Renewal. J Cell Physiol 2016;231:2361-7. [PMID: 27061836 DOI: 10.1002/jcp.25401] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
61 Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G, Zhang X. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012;7:e44265. [PMID: 22957056 DOI: 10.1371/journal.pone.0044265] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
62 Pasricha SR, Lim PJ, Duarte TL, Casu C, Oosterhuis D, Mleczko-Sanecka K, Suciu M, Da Silva AR, Al-Hourani K, Arezes J, McHugh K, Gooding S, Frost JN, Wray K, Santos A, Porto G, Repapi E, Gray N, Draper SJ, Ashley N, Soilleux E, Olinga P, Muckenthaler MU, Hughes JR, Rivella S, Milne TA, Armitage AE, Drakesmith H. Hepcidin is regulated by promoter-associated histone acetylation and HDAC3. Nat Commun 2017;8:403. [PMID: 28864822 DOI: 10.1038/s41467-017-00500-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
63 Kim H, Kim Y, Goh H, Jeoung D. Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs. Mol Cells 2016;39:229-41. [PMID: 26883907 DOI: 10.14348/molcells.2016.2244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kong LR, Tan TZ, Ong WR, Bi C, Huynh H, Lee SC, Chng WJ, Eichhorn PJA, Goh BC. Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma. Mol Oncol 2017;11:965-80. [PMID: 28397399 DOI: 10.1002/1878-0261.12064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
65 Soldi R, Cohen AL, Cheng L, Sun Y, Moos PJ, Bild AH. A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J 2013;13:94-104. [PMID: 22083351 DOI: 10.1038/tpj.2011.48] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
66 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ma P, Schultz RM. Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Dev Biol 2008;319:110-20. [PMID: 18501342 DOI: 10.1016/j.ydbio.2008.04.011] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 8.4] [Reference Citation Analysis]
68 He Y, Wang Z, Sun S, Tang D, Li W, Chai R, Li H. HDAC3 Is Required for Posterior Lateral Line Development in Zebrafish. Mol Neurobiol 2016;53:5103-17. [PMID: 26395281 DOI: 10.1007/s12035-015-9433-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
69 Buckwalter JM, Chan W, Shuman L, Wildermuth T, Ellis-Mohl J, Walter V, Warrick JI, Wu XR, Kaag M, Raman JD, DeGraff DJ. Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems. Int J Mol Sci 2019;20:E2599. [PMID: 31137849 DOI: 10.3390/ijms20102599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
70 Yan M, Qian YM, Yue CF, Wang ZF, Wang BC, Zhang W, Zheng FM, Liu Q. Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells. Oncotarget 2016;7:44171-84. [PMID: 27283770 DOI: 10.18632/oncotarget.9922] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
71 Kulka LAM, Fangmann PV, Panfilova D, Olzscha H. Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Front Cell Dev Biol 2020;8:425. [PMID: 32582706 DOI: 10.3389/fcell.2020.00425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
72 Roostaee A, Guezguez A, Beauséjour M, Simoneau A, Vachon PH, Levy E, Beaulieu JF. Histone deacetylase inhibition impairs normal intestinal cell proliferation and promotes specific gene expression. J Cell Biochem 2015;116:2695-708. [PMID: 26129821 DOI: 10.1002/jcb.25274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
73 Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y, Li S, Zeng Y, Lu QR, Huo Y, Shi Y, Bu H. HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition. Cancer Res 2019;79:3676-88. [PMID: 31097476 DOI: 10.1158/0008-5472.CAN-18-3767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
74 Lagger S, Meunier D, Mikula M, Brunmeir R, Schlederer M, Artaker M, Pusch O, Egger G, Hagelkruys A, Mikulits W, Weitzer G, Muellner EW, Susani M, Kenner L, Seiser C. Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J 2010;29:3992-4007. [PMID: 20967026 DOI: 10.1038/emboj.2010.264] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
75 Zhang L, Lu XF, Ji HJ, Zhou YJ, Wu ZR, Li L, Chen F, Bu H, Shi YJ. Ablation of histone deacetylase 3 in hepatocytes inhibits liver regeneration and induces apoptosis in mice. Shijie Huaren Xiaohua Zazhi 2015; 23(35): 5597-5605 [DOI: 10.11569/wcjd.v23.i35.5597] [Reference Citation Analysis]
76 Chang J, Chance MR, Nicholas C, Ahmed N, Guilmeau S, Flandez M, Wang D, Byun DS, Nasser S, Albanese JM, Corner GA, Heerdt BG, Wilson AJ, Augenlicht LH, Mariadason JM. Proteomic changes during intestinal cell maturation in vivo. J Proteomics 2008;71:530-46. [PMID: 18824147 DOI: 10.1016/j.jprot.2008.08.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
77 Schmitt HM, Schlamp CL, Nickells RW. Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury. J Ocul Pharmacol Ther 2018;34:260-73. [PMID: 29211617 DOI: 10.1089/jop.2017.0059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
78 Yu JI, Choi C, Shin SW, Son A, Lee GH, Kim SY, Park HC. Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation. Sci Rep 2017;7:14986. [PMID: 29118323 DOI: 10.1038/s41598-017-15165-3] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
79 Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, Shin DG, Rosenberg DW, Giardina C. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther 2008;7:1570-80. [PMID: 18769117 DOI: 10.4161/cbt.7.10.6561] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
80 Bassett SA, Barnett MP. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients 2014;6:4273-301. [PMID: 25322459 DOI: 10.3390/nu6104273] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis]
81 Wang Y, Frank DB, Morley MP, Zhou S, Wang X, Lu MM, Lazar MA, Morrisey EE. HDAC3-Dependent Epigenetic Pathway Controls Lung Alveolar Epithelial Cell Remodeling and Spreading via miR-17-92 and TGF-β Signaling Regulation. Dev Cell 2016;36:303-15. [PMID: 26832331 DOI: 10.1016/j.devcel.2015.12.031] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
82 Kaliszczak M, Trousil S, Åberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer 2013;108:342-50. [PMID: 23322205 DOI: 10.1038/bjc.2012.576] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
83 Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013;32:599-609. [PMID: 22391568 DOI: 10.1038/onc.2012.81] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 10.3] [Reference Citation Analysis]
84 Alenghat T, Artis D. Epigenomic regulation of host-microbiota interactions. Trends Immunol. 2014;35:518-525. [PMID: 25443494 DOI: 10.1016/j.it.2014.09.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
85 Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci 2011;68:709-20. [PMID: 20706768 DOI: 10.1007/s00018-010-0480-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
86 Pufahl L, Katryniok C, Schnur N, Sorg BL, Metzner J, Grez M, Steinhilber D. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3. J Cell Mol Med 2012;16:1461-73. [PMID: 21883892 DOI: 10.1111/j.1582-4934.2011.01420.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
87 Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol 2014;14:10. [PMID: 24624923 DOI: 10.1186/1472-6890-14-10] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
88 Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol 2015;8:82. [PMID: 26156322 DOI: 10.1186/s13045-015-0176-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
89 Killick-Cole CL, Singleton WGB, Bienemann AS, Asby DJ, Wyatt MJ, Boulter LJ, Barua NU, Gill SS. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. PLoS One 2017;12:e0176855. [PMID: 28542253 DOI: 10.1371/journal.pone.0176855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
90 Mariadason JM. Making sense of HDAC2 mutations in colon cancer. Gastroenterology 2008;135:1457-9. [PMID: 18851967 DOI: 10.1053/j.gastro.2008.09.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
91 Chen HP, Zhao YT, Zhao TC. Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog. 2015;20:35-47. [PMID: 25746103 DOI: 10.1615/critrevoncog.2015012997] [Cited by in Crossref: 121] [Cited by in F6Publishing: 70] [Article Influence: 17.3] [Reference Citation Analysis]
92 Dhar SS, Alam H, Li N, Wagner KW, Chung J, Ahn YW, Lee MG. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem 2014;289:7483-96. [PMID: 24482232 DOI: 10.1074/jbc.M113.521625] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
93 Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci (Schol Ed) 2012;4:831-9. [PMID: 22202094 DOI: 10.2741/s303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
94 Rajendran P, Kidane AI, Yu TW, Dashwood WM, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics. 2013;8:612-623. [PMID: 23770684 DOI: 10.4161/epi.24710] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
95 Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 2009;125:774-82. [PMID: 19384952 DOI: 10.1002/ijc.24325] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
96 Hrgovic I, Doll M, Kleemann J, Wang XF, Zoeller N, Pinter A, Kippenberger S, Kaufmann R, Meissner M. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer 2016;16:763. [PMID: 27716272 DOI: 10.1186/s12885-016-2807-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
97 Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y. Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J 2014;28:4265-79. [PMID: 24948597 DOI: 10.1096/fj.14-250654] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
98 Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1:19-25. [PMID: 19383284 DOI: 10.1016/j.molonc.2007.01.001] [Cited by in Crossref: 542] [Cited by in F6Publishing: 525] [Article Influence: 36.1] [Reference Citation Analysis]
99 Waby JS, Bingle CD, Corfe BM. Post-translational control of sp-family transcription factors. Curr Genomics 2008;9:301-11. [PMID: 19471608 DOI: 10.2174/138920208785133244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
100 Wang H, Liu YC, Zhu CY, Yan F, Wang MZ, Chen XS, Wang XK, Pang BX, Li YH, Liu DH, Gao CJ, Liu SJ, Dou LP. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. J Exp Clin Cancer Res 2020;39:278. [PMID: 33298132 DOI: 10.1186/s13046-020-01792-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Salvador LA, Luesch H. Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets 2012;13:1029-47. [PMID: 22594471 DOI: 10.2174/138945012802008973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
102 Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J 2016;52:1-11. [PMID: 26865995 DOI: 10.4068/cmj.2016.52.1.1] [Cited by in Crossref: 168] [Cited by in F6Publishing: 163] [Article Influence: 28.0] [Reference Citation Analysis]
103 Basu N, Saha S, Khan I, Ramachandra SG, Visweswariah SS. Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21. J Biol Chem 2014;289:581-93. [PMID: 24217248 DOI: 10.1074/jbc.M113.511311] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
104 Kakiuchi A, Kakuki T, Ohwada K, Kurose M, Kondoh A, Obata K, Nomura K, Miyata R, Kaneko Y, Konno T, Kohno T, Himi T, Takano KI, Kojima T. HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63‑mediated tight junction molecules and p21‑mediated growth arrest. Oncol Rep 2021;45:46. [PMID: 33649777 DOI: 10.3892/or.2021.7997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Kwon DH, Ryu J, Kim YK, Kook H. Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification. Int J Mol Sci 2020;21:E3246. [PMID: 32375326 DOI: 10.3390/ijms21093246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
106 Negmeldin AT, Knoff JR, Pflum MKH. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 2018;143:1790-806. [PMID: 29150330 DOI: 10.1016/j.ejmech.2017.10.076] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
107 Trivedi CM, Lu MM, Wang Q, Epstein JA. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem 2008;283:26484-9. [PMID: 18625706 DOI: 10.1074/jbc.M803686200] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
108 Fetahu IS, Höbaus J, Kállay E. Vitamin D and the epigenome. Front Physiol. 2014;5:164. [PMID: 24808866 DOI: 10.3389/fphys.2014.00164] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 17.6] [Reference Citation Analysis]
109 Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 2011;12:484-93. [PMID: 21738006 DOI: 10.4161/cbt.12.6.15956] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
110 Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010; 1(5): 55-61 [PMID: 21540990 DOI: 10.4331/wjbc.v1.i5.55] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
111 Patil H, Wilks C, Gonzalez RW, Dhanireddy S, Conrad-Webb H, Bergel M. Mitotic Activation of a Novel Histone Deacetylase 3-Linker Histone H1.3 Protein Complex by Protein Kinase CK2. J Biol Chem 2016;291:3158-72. [PMID: 26663086 DOI: 10.1074/jbc.M115.643874] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
112 Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Breast Cancer Res Treat 2015;151:281-94. [PMID: 25904215 DOI: 10.1007/s10549-015-3376-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
113 Stintzing S, Kemmerling R, Kiesslich T, Alinger B, Ocker M, Neureiter D. Myelodysplastic syndrome and histone deacetylase inhibitors: “to be or not to be acetylated”. J Biomed Biotechnol. 2011;2011:214143. [PMID: 21629744 DOI: 10.1155/2011/214143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
114 Sun D, Chen Y, Fang JY. Influence of the microbiota on epigenetics in colorectal cancer. Natl Sci Rev 2019;6:1138-48. [PMID: 34691992 DOI: 10.1093/nsr/nwy160] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
115 Thomas EA, D'Mello SR. Complex neuroprotective and neurotoxic effects of histone deacetylases. J Neurochem 2018;145:96-110. [PMID: 29355955 DOI: 10.1111/jnc.14309] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
116 Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, Jürgens H, Kool M, Görlich D, Eveslage M, Jung M, Meisterernst M, Frühwald M. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer 2013;13:286. [PMID: 23764045 DOI: 10.1186/1471-2407-13-286] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
117 Wu SE, Hashimoto-Hill S, Woo V, Eshleman EM, Whitt J, Engleman L, Karns R, Denson LA, Haslam DB, Alenghat T. Microbiota-derived metabolite promotes HDAC3 activity in the gut. Nature 2020;586:108-12. [PMID: 32731255 DOI: 10.1038/s41586-020-2604-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
118 Swain SD, Grifka-Walk HN, Gripentrog J, Lehmann M, Deuling B, Jenkins B, Liss H, Blaseg N, Bimczok D, Kominsky DJ. Slug and Snail have differential effects in directing colonic epithelial wound healing and partially mediate the restitutive effects of butyrate. Am J Physiol Gastrointest Liver Physiol 2019;317:G531-44. [PMID: 31393789 DOI: 10.1152/ajpgi.00071.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J, Zheng SS. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 2010;5:e14460. [PMID: 21206745 DOI: 10.1371/journal.pone.0014460] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
120 West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9. [PMID: 24382387 DOI: 10.1172/JCI69738] [Cited by in Crossref: 832] [Cited by in F6Publishing: 490] [Article Influence: 104.0] [Reference Citation Analysis]
121 Gong W, Wu R, Zhang Y. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study. J Comput Chem 2015;36:2228-35. [PMID: 26452222 DOI: 10.1002/jcc.24203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
122 Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, Zhao LY, Li JL, Wang Y, Wang Y, Ma H, Hodder P, Roush WR, Liao D. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem Biol 2015;22:273-84. [PMID: 25699604 DOI: 10.1016/j.chembiol.2014.12.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
123 Mao P, He W, Mai X, Feng L, Li N, Liao Y, Zhu C, Li J, Chen T, Liu S, Zhang Q, He L. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 2021. [DOI: 10.1016/j.bmc.2021.116599] [Reference Citation Analysis]
124 Pchejetski D, Alfraidi A, Sacco K, Alshaker H, Muhammad A, Monzon L. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol 2016;142:1659-71. [PMID: 26560874 DOI: 10.1007/s00432-015-2064-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
125 Pai JT, Hsu CY, Hua KT, Yu SY, Huang CY, Chen CN, Liao CH, Weng MS. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. Molecules 2015;20:8000-19. [PMID: 25946558 DOI: 10.3390/molecules20058000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
126 Caslini C, Hong S, Ban YJ, Chen XS, Ince TA. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene 2019;38:6599-614. [PMID: 31375747 DOI: 10.1038/s41388-019-0897-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
127 Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl Med Biol 2011;38:683-96. [PMID: 21718944 DOI: 10.1016/j.nucmedbio.2010.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
128 Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, DuBois RN. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008;68:9331-7. [PMID: 19010907 DOI: 10.1158/0008-5472.CAN-08-2893] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
129 Noor Z, Afzal N, Rashid S. Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One 2015;10:e0139588. [PMID: 26431201 DOI: 10.1371/journal.pone.0139588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
130 Sobolewski C, Sanduja S, Blanco FF, Hu L, Dixon DA. Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. Biomolecules. 2015;5:2035-2055. [PMID: 26343742 DOI: 10.3390/biom5032035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
131 Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR. Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. Pharmaceuticals (Basel) 2011;4:1183-95. [PMID: 22582024 DOI: 10.3390/ph4081183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
132 Uba Aİ, Yelekçi K. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turk J Biol 2017;41:901-18. [PMID: 30814855 DOI: 10.3906/biy-1701-26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
133 Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC, Yang CN, Lee SH, Liu SH, Shen LW, Chiu CS, Arbiser JL, Meng M, Sheu ML. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. Cell Biol Toxicol 2022. [PMID: 34973135 DOI: 10.1007/s10565-021-09673-2] [Reference Citation Analysis]
134 Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007;27:4784-95. [PMID: 17470557 DOI: 10.1128/MCB.00494-07] [Cited by in Crossref: 168] [Cited by in F6Publishing: 99] [Article Influence: 11.2] [Reference Citation Analysis]
135 Saha B, Parks RJ. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication. J Virol 2019;93:e00088-19. [PMID: 30944181 DOI: 10.1128/JVI.00088-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
136 Kang ZH, Wang CY, Zhang WL, Zhang JT, Yuan CH, Zhao PW, Lin YY, Hong S, Li CY, Wang L. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One 2014;9:e98894. [PMID: 24896240 DOI: 10.1371/journal.pone.0098894] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
137 Xiao T, Wu S, Yan C, Zhao C, Jin H, Yan N, Xu J, Wu Y, Li C, Shao Q, Xia S. Butyrate upregulates the TLR4 expression and the phosphorylation of MAPKs and NK-κB in colon cancer cell in vitro. Oncol Lett 2018;16:4439-47. [PMID: 30214578 DOI: 10.3892/ol.2018.9201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
138 Ahmad R, Kumar B, Pan K, Dhawan P, Singh AB. HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation. Oncotarget 2017;8:87718-36. [PMID: 29152115 DOI: 10.18632/oncotarget.21190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
139 Islam S, Espitia CM, Persky DO, Carew JS, Nawrocki ST. Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy. Blood Adv 2020;4:5297-310. [PMID: 33108458 DOI: 10.1182/bloodadvances.2020002297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013;13:497-510. [PMID: 23760024 DOI: 10.1038/nrc3486] [Cited by in Crossref: 402] [Cited by in F6Publishing: 338] [Article Influence: 44.7] [Reference Citation Analysis]
141 Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CY, Wu M, Zhang LJ, Hersey P, Scolyer RA, Zhang XD. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun 2013;4:1508. [PMID: 23443536 DOI: 10.1038/ncomms2489] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
142 Luna Coronell JA, Sergelen K, Hofer P, Gyurján I, Brezina S, Hettegger P, Leeb G, Mach K, Gsur A, Weinhäusel A. The Immunome of Colon Cancer: Functional In Silico Analysis of Antigenic Proteins Deduced from IgG Microarray Profiling. Genomics Proteomics Bioinformatics 2018;16:73-84. [PMID: 29505855 DOI: 10.1016/j.gpb.2017.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
143 Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher A, Fedorowicz G, Vallero R, Ortwine DF, Gunzner J, Modrusan Z, Neumann L, Koth CM, Lupardus PJ, Kaminker JS, Heise CE, Steiner P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 2013;288:26926-43. [PMID: 23897821 DOI: 10.1074/jbc.M113.490706] [Cited by in Crossref: 230] [Cited by in F6Publishing: 88] [Article Influence: 25.6] [Reference Citation Analysis]
144 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
145 Giardina C, Madigan JP, Tierney CA, Brenner BM, Rosenberg DW. Vitamin D resistance and colon cancer prevention. Carcinogenesis 2012;33:475-82. [PMID: 22180570 DOI: 10.1093/carcin/bgr301] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
146 Rajendran P, Delage B, Dashwood WM, Yu TW, Wuth B, Williams DE, Ho E, Dashwood RH. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol Cancer. 2011;10:68. [PMID: 21624135 DOI: 10.1186/1476-4598-10-68] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 7.4] [Reference Citation Analysis]
147 New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6:637-56. [PMID: 23141799 DOI: 10.1016/j.molonc.2012.09.003] [Cited by in Crossref: 217] [Cited by in F6Publishing: 204] [Article Influence: 21.7] [Reference Citation Analysis]
148 Stebe-Frick S, Ostaff MJ, Stange EF, Malek NP, Wehkamp J. Histone deacetylase-mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured tissue. Sci Rep 2018;8:12886. [PMID: 30150730 DOI: 10.1038/s41598-018-31125-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
149 Kee HJ, Kim GR, Lin MQ, Choi SY, Ryu Y, Jin L, Piao ZH, Jeong MH. Expression of Class I and Class II a/b Histone Deacetylase is Dysregulated in Hypertensive Animal Models. Korean Circ J 2017;47:392-400. [PMID: 28567090 DOI: 10.4070/kcj.2016.0266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
150 Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One 2013;8:e58267. [PMID: 23469273 DOI: 10.1371/journal.pone.0058267] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
151 Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017;18. [PMID: 28671573 DOI: 10.3390/ijms18071414] [Cited by in Crossref: 468] [Cited by in F6Publishing: 434] [Article Influence: 93.6] [Reference Citation Analysis]
152 Lou T, Liu C, Qu H, Zhang Z, Wang S, Zhuang H. FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma. J Transl Med 2022;20:19. [PMID: 34991620 DOI: 10.1186/s12967-021-03224-3] [Reference Citation Analysis]
153 Mariadason JM. Dissecting HDAC3-mediated tumor progression. Cancer Biol Ther 2008;7:1581-3. [PMID: 18787408 DOI: 10.4161/cbt.7.10.6863] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
154 Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604-610. [PMID: 18212746 DOI: 10.1038/sj.bjc.6604199] [Cited by in Crossref: 321] [Cited by in F6Publishing: 307] [Article Influence: 22.9] [Reference Citation Analysis]
155 Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One. 2013;8:e76340. [PMID: 24130769 DOI: 10.1371/journal.pone.0076340] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
156 Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One 2012;7:e43645. [PMID: 22928010 DOI: 10.1371/journal.pone.0043645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
157 Li Y, Li X, Guo B. Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res 2010;70:646-54. [PMID: 20068155 DOI: 10.1158/0008-5472.CAN-09-1924] [Cited by in Crossref: 80] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
158 Sodeifian G, Saadati Ardestani N, Sajadian SA, Golmohammadi MR, Fazlali A. Prediction of Solubility of Sodium Valproate in Supercritical Carbon Dioxide: Experimental Study and Thermodynamic Modeling. J Chem Eng Data 2020;65:1747-60. [DOI: 10.1021/acs.jced.9b01069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 8.5] [Reference Citation Analysis]
159 López JE, Sullivan ED, Fierke CA. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators. ACS Chem Biol 2016;11:706-16. [PMID: 26907466 DOI: 10.1021/acschembio.5b01067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
160 Dávalos-Salas M, Montgomery MK, Reehorst CM, Nightingale R, Ng I, Anderton H, Al-Obaidi S, Lesmana A, Scott CM, Ioannidis P, Kalra H, Keerthikumar S, Tögel L, Rigopoulos A, Gong SJ, Williams DS, Yoganantharaja P, Bell-Anderson K, Mathivanan S, Gibert Y, Hiebert S, Scott AM, Watt MJ, Mariadason JM. Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity. Nat Commun 2019;10:5291. [PMID: 31757939 DOI: 10.1038/s41467-019-13180-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
161 Prasad R, Katiyar SK. Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage. Genes Cancer 2015;6:49-61. [PMID: 25821561 DOI: 10.18632/genesandcancer.52] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
162 Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010;16:3786-94. [PMID: 20463088 DOI: 10.1158/1078-0432.CCR-10-0547] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
163 Giardina C, Nakanishi M, Khan A, Kuratnik A, Xu W, Brenner B, Rosenberg DW. Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas. Cancer Prev Res (Phila) 2015;8:387-99. [PMID: 25873367 DOI: 10.1158/1940-6207.CAPR-14-0371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
164 Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013;7:47-60. [PMID: 23459471 DOI: 10.2147/btt.s29965] [Cited by in Crossref: 30] [Cited by in F6Publishing: 100] [Article Influence: 3.3] [Reference Citation Analysis]
165 Sferra R, Pompili S, Festuccia C, Marampon F, Gravina GL, Ventura L, Di Cesare E, Cicchinelli S, Gaudio E, Vetuschi A. The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study. Eur J Histochem 2017;61:2732. [PMID: 28735518 DOI: 10.4081/ejh.2017.2732] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
166 Bu Q, Cui L, Li J, Du X, Zou W, Ding K, Pan J. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther 2014;15:951-62. [PMID: 24759597 DOI: 10.4161/cbt.28931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
167 Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. J Med Chem 2014;57:3324-41. [PMID: 24694055 DOI: 10.1021/jm401877m] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 6.5] [Reference Citation Analysis]
168 Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011;2011:830260. [PMID: 21629704 DOI: 10.1155/2011/830260] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
169 Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr 2008;28:347-66. [PMID: 18598138 DOI: 10.1146/annurev.nutr.28.061807.155354] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
170 Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010;5:275-9. [PMID: 20035240 DOI: 10.1097/JTO.0b013e3181c5e366] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
171 Ishii S, Kurasawa Y, Wong J, Yu-Lee LY. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci USA. 2008;105:4179-4184. [PMID: 18326024 DOI: 10.1073/pnas.0710140105] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
172 Schilderink R, Verseijden C, de Jonge WJ. Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis. Front Immunol. 2013;4:226. [PMID: 23914191 DOI: 10.3389/fimmu.2013.00226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
173 Triki M, Lapierre M, Cavailles V, Mokdad-Gargouri R. Expression and role of nuclear receptor coregulators in colorectal cancer. World J Gastroenterol 2017; 23(25): 4480-4490 [PMID: 28740336 DOI: 10.3748/wjg.v23.i25.4480] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
174 Stanilov NS, Miteva L, Cirovski G, Stanilova SA. Increased transforming growth factor β and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients. Contemp Oncol (Pozn) 2016;20:458-62. [PMID: 28239283 DOI: 10.5114/wo.2016.65605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
175 Sato A. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther 2012;5:67-76. [PMID: 22573938 DOI: 10.2147/OTT.S23874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
176 Birkenkamp-Demtroder K, Mansilla F, Sørensen FB, Kruhøffer M, Cabezón T, Christensen LL, Aaltonen LA, Verspaget HW, Ørntoft TF. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol. 2007;1:181-195. [PMID: 19383294 DOI: 10.1016/j.molonc.2007.05.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
177 Jiang Y, Hsieh J. HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc Natl Acad Sci U S A. 2014;111:13541-13546. [PMID: 25161285 DOI: 10.1073/pnas.1411939111] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
178 Zeineldin M, Neufeld KL. More than two decades of Apc modeling in rodents. Biochim Biophys Acta. 2013;1836:80-89. [PMID: 23333833 DOI: 10.1016/j.bbcan.2013.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
179 Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, Chiocca S, Propst F, Weitzer G, Seiser C. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol 2010;30:1171-81. [PMID: 20028735 DOI: 10.1128/MCB.01500-09] [Cited by in Crossref: 90] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
180 Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG Jr, Neder L, Scrideli CA, Tone LG. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008;8:243. [PMID: 18713462 DOI: 10.1186/1471-2407-8-243] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
181 Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009;147:515-25. [PMID: 19775297 DOI: 10.1111/j.1365-2141.2009.07887.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
182 Foley C, Mitsiades N. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer 2016;7:84-103. [PMID: 26728473 DOI: 10.1007/s12672-015-0239-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
183 Zhang Y, Zheng X, Tan H, Lu Y, Tao D, Liu Y, Ma Y. PIWIL2 suppresses Siah2-mediated degradation of HDAC3 and facilitates CK2α-mediated HDAC3 phosphorylation. Cell Death Dis 2018;9:423. [PMID: 29555935 DOI: 10.1038/s41419-018-0462-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
184 Liu Y, Salvador LA, Byeon S, Ying Y, Kwan JC, Law BK, Hong J, Luesch H. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther. 2010;335:351-361. [PMID: 20739454 DOI: 10.1124/jpet.110.172387] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
185 Kanda K, Sakamoto J, Matsumoto Y, Ikuta K, Goto N, Morita Y, Ohno M, Nishi K, Eto K, Kimura Y, Nakanishi Y, Ikegami K, Yoshikawa T, Fukuda A, Kawada K, Sakai Y, Ito A, Yoshida M, Kimura T, Chiba T, Nishi E, Seno H. Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation. JCI Insight 2018;3:91316. [PMID: 29669932 DOI: 10.1172/jci.insight.91316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
186 Schmitt F, Gosch LC, Dittmer A, Rothemund M, Mueller T, Schobert R, Biersack B, Volkamer A, Höpfner M. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function. Int J Mol Sci 2019;20:E383. [PMID: 30658435 DOI: 10.3390/ijms20020383] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
187 Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW, Hiebert SW. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30:61-72. [PMID: 18406327 DOI: 10.1016/j.molcel.2008.02.030] [Cited by in Crossref: 227] [Cited by in F6Publishing: 230] [Article Influence: 16.2] [Reference Citation Analysis]
188 Xu G, Zhu H, Zhang M, Xu J. Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5. Int J Mol Med 2018;41:155-63. [PMID: 29115379 DOI: 10.3892/ijmm.2017.3225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
189 Adikesavan AK, Karmakar S, Pardo P, Wang L, Liu S, Li W, Smith CL. Activation of p53 transcriptional activity by SMRT: a histone deacetylase 3-independent function of a transcriptional corepressor. Mol Cell Biol 2014;34:1246-61. [PMID: 24449765 DOI: 10.1128/MCB.01216-13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
190 Jung SB, Kim CS, Naqvi A, Yamamori T, Mattagajasingh I, Hoffman TA, Cole MP, Kumar A, Dericco JS, Jeon BH, Irani K. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res 2010;107:877-87. [PMID: 20705923 DOI: 10.1161/CIRCRESAHA.110.222968] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
191 Jeong MH, Ko H, Jeon H, Sung GJ, Park SY, Jun WJ, Lee YH, Lee J, Lee SW, Yoon HG, Choi KC. Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells. Oncotarget 2016;7:56767-80. [PMID: 27462923 DOI: 10.18632/oncotarget.10790] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
192 Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-77. [PMID: 18671804 DOI: 10.1111/j.0309-0167.2008.03109.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
193 Chüeh AC, Tse JWT, Dickinson M, Ioannidis P, Jenkins L, Togel L, Tan B, Luk I, Davalos-Salas M, Nightingale R, Thompson MR, Williams BRG, Lessene G, Lee EF, Fairlie WD, Dhillon AS, Mariadason JM. ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. Clin Cancer Res 2017;23:5573-84. [PMID: 28611196 DOI: 10.1158/1078-0432.CCR-17-0466] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
194 Osipovich AB, Gangula R, Vianna PG, Magnuson MA. Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation. Development 2016;143:4595-607. [PMID: 27864380 DOI: 10.1242/dev.141465] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
195 Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan JL, Bonine-Summers AR. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell. 2010;18:436-447. [PMID: 21075309 DOI: 10.1016/j.ccr.2010.10.022] [Cited by in Crossref: 236] [Cited by in F6Publishing: 235] [Article Influence: 19.7] [Reference Citation Analysis]
196 Han A, Bennett N, Ahmed B, Whelan J, Donohoe DR. Butyrate decreases its own oxidation in colorectal cancer cells through inhibition of histone deacetylases. Oncotarget. 2018;9:27280-27292. [PMID: 29930765 DOI: 10.18632/oncotarget.25546] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
197 Gurard-Levin ZA, Kilian KA, Kim J, Bähr K, Mrksich M. Peptide arrays identify isoform-selective substrates for profiling endogenous lysine deacetylase activity. ACS Chem Biol 2010;5:863-73. [PMID: 20849068 DOI: 10.1021/cb100088g] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
198 Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, Nam JH. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 2008;19:185-90. [PMID: 19471575 DOI: 10.3802/jgo.2008.19.3.185] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
199 Chen CY, Fang JY, Chen CC, Chuang WY, Leu YL, Ueng SH, Wei LS, Cheng SF, Hsueh C, Wang TH. 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression. Front Oncol 2020;10:1319. [PMID: 32850418 DOI: 10.3389/fonc.2020.01319] [Reference Citation Analysis]
200 Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008;29:1816-24. [PMID: 18628250 DOI: 10.1093/carcin/bgn165] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 6.9] [Reference Citation Analysis]
201 Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009;297:F996-F1005. [PMID: 19640900 DOI: 10.1152/ajprenal.00282.2009] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 11.9] [Reference Citation Analysis]
202 Tsai SY, Chuang JY, Tsai MS, Wang XF, Xi ZX, Hung JJ, Chang WC, Bonci A, Su TP. Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proc Natl Acad Sci U S A 2015;112:E6562-70. [PMID: 26554014 DOI: 10.1073/pnas.1518894112] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 9.9] [Reference Citation Analysis]
203 Liu TQ, Sun MJ, Wei MJ. Clinical pathological significance of expression of histone deacetylase 1 and 2 in colorectal adenoma and carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(30): 3195-3199 [DOI: 10.11569/wcjd.v18.i30.3195] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Salimi V, Shahsavari Z, Safizadeh B, Hosseini A, Khademian N, Tavakoli-Yaraki M. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment. Lipids Health Dis. 2017;16:208. [PMID: 29096636 DOI: 10.1186/s12944-017-0593-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]